Prakash Kotagal, MD
Neurological Surgery · Cleveland, OHNPI 1053350983
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Eisai Inc. at 46.3% of the total. Reporting peaked in 2019 at $24,549 and has fallen 92.5% since, to $1,836 in 2025. Among neurological surgery clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $493.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$38K
- UCB, Inc.$13K
- Livanova USA, Inc.$7K
- Neurelis, Inc.$6K
- SK Life Science, Inc.$6K
- Supernus Pharmaceuticals, Inc.$6K
- plus $7K from 8 others
What the payments were for
- Consulting fees$25,85731%
- Speaking & faculty fees$42,05151%
- Travel & lodging$8,82611%
- Food & beverage$5,5677%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 59 | $38,087 |
| UCB, Inc. | 42 | $12,670 |
| Livanova USA, Inc. | 10 | $7,318 |
| Neurelis, Inc. | 11 | $6,175 |
| SK Life Science, Inc. | 9 | $5,949 |
| Supernus Pharmaceuticals, Inc. | 14 | $5,570 |
| Biocodex, Inc. | 8 | $2,824 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,668 |
| Jazz Pharmaceuticals Inc. | 6 | $627 |
| Zogenix Inc. | 1 | $130 |
| Mallinckrodt Enterprises LLC | 1 | $110 |
| Greenwich Biosciences, Inc. | 1 | $106 |
| Mallinckrodt Hospital Products Inc. | 1 | $82 |
| Sunovion Pharmaceuticals Inc. | 3 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$27,500
- Banzel$9,741
- VALTOCO$5,950
- XCOPRI$5,746
- OXTELLAR XR$5,207
- VNS - Sentiva$4,420
- Briviact$3,683
- DIACOMIT$2,605
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$2,294
- Vimpat$2,000
- Fintepla$1,571
- Epidiolex$573
- VNS Therapy$417
- Nayzilam$339
- ACTHAR$110
How this compares
$82,338 in reported general payments places this provider in the 90th percentile of 301 neurological surgery providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine | 13 | $212 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Cleveland
- Abdi MohitCleveland$884K
- Mark BainCleveland$242K
- Pablo RecinosCleveland$211K
- Michael SteinmetzCleveland$168K
- Josue Avecillas ChasinCleveland$144K
- Gene BarnettCleveland$135K
- Ajit KrishnaneyCleveland$76K
- Gabriel SmithCleveland$72K
- Peter RasmussenCleveland$58K
- Tiffany HodgesCleveland$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.